HP-228 (Trega Biosciences Inc).
HP-228 is a cytokine regulating agent from Trega Biosciences (formerly Houghten Pharmaceuticals). It is in phase II trials for the management of post-surgical pain and inflammation [195065]. The drug was indicated for the treatment of diabetes, obesity and chemotherapy-induced toxicity, but Trega has decided to discontinue the development of HP-228 for these indications [259339].